CClinicalTrials.gg
RecruitingNCT03855800Updated Jun 2, 2026

Molecular Detection of Advanced Neoplasia in Pancreatic Cysts

An interventional study of Blood, stool, pancreatic juice and cyst fluid collection and Pancreatic Surgery in Pancreas Cyst, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled May 2018, registered Jan 2019).
  • Started May 2018; still recruiting 8 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Non-randomized
Ages
18 Years to 120 Years
Sex
All
01

Study summary

Researchers are trying to find out whether new tests ("biomarkers") of blood, stool, pancreas cyst fluid, or pancreas juice can be used to diagnose malignant or pre-malignant changes in pancreas cysts.

Read the detailed description

Subjects with Fukuoka Worrisome (FW) or Fukuoka High Risk (FHR) pancreatic cysts will be enrolled and assigned to Immediate Surgery or Clinical Follow-up groups based on clinical management as determined by the treating physicians. Blood, stool, pancreas cyst fluid, and pancreas juice specimens will be collected from participants.

02

Conditions studied

  • Pancreas Cyst

Browse trials for

03

In context

Pancreatic Cyst

94 studies on the registry are indexed under Pancreatic Cyst; 34 are open to participants now.

This study's planned enrollment of 800 is above the median of 67 across 40 interventional studies indexed under Pancreatic Cyst.

Browse Pancreatic Cyst studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with pancreatic cystic lesions meeting Fukuoka worrisome or Fukuoka high-risk criteris
  • Patients with suspected cystic neoplasm of the pancreas
  • Able to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Pregnant and/or nursing
  • Incarceration
  • Imaging showing possible pancreatic cancer
  • Prior history of pancreatic cancer or pancreatic surgery
  • History of receiving systemic chemotherapy or abdominal radiation within the last 5 years
  • Previous therapy for a pancreatic cystic lesion
  • History of pancreatic necrosis
  • Diagnosis of cancer (other than non-melanoma skin cancer) within the last 5 years
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Clinical Follow-up

    Participants not undergoing surgery will be assigned to the "Clinical Follow-up" study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. All participants in the Clinical Follow-up group will be contacted yearly for a telephone interview until they undergo surgery, die, receive a diagnosis that excludes them from the study, or for 5 years, and interval medical records will be obtained and reviewed. During follow-up results of clinically indicated follow-up imaging studies will be abstracted

    Diagnostic Test: Blood, stool, pancreatic juice and cyst fluid collection · Procedure: Endoscopy Exam

  • Other
    Surgical

    Participants scheduled for surgical resection after their initial clinical evaluation will be assigned to the "Immediate Surgery" study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. Participants in the Immediate Surgery group will be followed until the surgical pathology of their pancreatic cyst is known.

    Diagnostic Test: Blood, stool, pancreatic juice and cyst fluid collection · Procedure: Pancreatic Surgery

Interventions

  • Diagnostic testBlood, stool, pancreatic juice and cyst fluid collection

    Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.

  • ProcedurePancreatic Surgery

    Surgical resection of pancreatic cyst

  • ProcedureEndoscopy Exam

    Clinically indicated endoscopic ultrasound

06

What researchers measure

Primary outcomes

  1. Biospecimen Acquisition

    Number of biospecimens collected

    Time frame: 5 years

  2. High grade dysplasia (HGD) or cancer diagnosis in Immediate Surgery group

    To validate the diagnostic accuracy of cyst fluid methylated DNA marker (MDM) assays for detection of HGD and cancer in pancreatic cysts undergoing surgical resection

    Time frame: 5 years

Secondary outcomes

  1. High grade dysplasia (HGD) or cancer diagnosis in clinical follow up group

    To evaluate the performance of cyst fluid MDM assays for predicting development of HGD or cancer during 3-year follow-up in study patients who are initially managed non-operatively

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03855800
Lead sponsor
Mayo Clinic
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Feb 27, 2019
Start date
May 11, 2018
Primary completion
Dec 30, 2030 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Jun 2, 2026

Study contacts

IN-CYST Team
Contact
rstincyststudy@mayo.edu
1-833-250-5364 ext. 2
Shounak Majumder, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion